Innate lymphoid cells sustain colon cancer through production of interleukin-22 in a mouse model
Open accessThe DOI matches its Crossref record; 50 of the 52 references it cites were found in a registry or an index.
Abstract
Patients with inflammatory bowel disease (IBD) have an increased risk of colon cancer. However, the immune cells and cytokines that mediate the transition from intestinal inflammation to cancer are poorly understood. We show that bacteria-induced colon cancer is accompanied by differential accumulation of IL-17(+)IL-22(+) colonic innate lymphoid cells (cILCs), which are phenotypically distinct from LTi and NK-22 cells, and that their depletion in mice with dysplastic inflammation blocks the development of invasive colon cancer. Analysis of the functional role of distinct Type 17 cytokines shows that although blockade of IL-17 inhibits some parameters of intestinal inflammation, reduction in dysplasia and colorectal cancer (CRC) requires neutralization of IL-22 indicating a unique role for IL-22 in the maintenance of cancer in this model. Mechanistic analyses showed that IL-22 selectively acts on epithelial cells to induce Stat3 phosphorylation and proliferation. Importantly, we could detect IL-22(+)CD3(+) and IL-22(+)CD3(−) cells in human CRC. Our results describe a new activity of IL-22 in the colon as a nonredundant mediator of the inflammatory cascade required for perpetuation of CRC, highlighting the IL-22 axis as a novel therapeutic target in colon cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although known to exert a tumor-promoting effect in colorectal cancer (Kirchberger et al., 2013; Wang et al., 2017)”
From Commensal Microbiota Promote Lung Cancer Development via γδ T Cells (2019) · cites this paper as Kirchberger et al., 2013
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Genome-Wide Association Study Identifies IL23R as an Inflammatory Bowel Disease Gene
Duerr, R. H., Taylor, K. D., Brant, S. R., Rioux, J. D., Silverberg, M. S., Daly, M. J., Steinhart, A. H., Abraham, C., Regueiro, M., Griffiths, A., et al. (2006) · Science · doi:10.1126/science.1135245 · Cited by 3,039 · cited 1×
“…in many mouse models (Hue et al., 2006; Izcue et al., 2008), and its components IL-23R and Stat3 are not only associated with IBD susceptibility (Duerr et al., 2006; Barrett et al., 2008) but also involved in inflammation-associated cancer in the skin and colon (Langowski et al., 2006; Bollrath…”
BackgroundThe risk of colorectal cancer in ulcerative colitis: a meta-analysis
Eaden, J. A., Abrams, K. R., & Mayberry, J. F. (2001) · Gut · doi:10.1136/gut.48.4.526 · Cited by 2,959 · cited 1×
“In inflammatory bowel disease (IBD) patients, deranged inflammatory responses toward the intestinal microbiota increase the risk of colon cancer twofold (Eaden et al., 2001).”
BackgroundGenome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
the NIDDK IBD Genetics Consortium, Barrett, J. C., the Belgian-French IBD Consortium, the Wellcome Trust Case Control Consortium, Hansoul, S., Nicolae, D. L., Cho, J. H., Duerr, R. H., Rioux, J. D., Brant, S. R., et al. (2008) · Nature Genetics · doi:10.1038/ng.175 · Cited by 2,593 · cited 1×
“…(Hue et al., 2006; Izcue et al., 2008), and its components IL-23R and Stat3 are not only associated with IBD susceptibility (Duerr et al., 2006; Barrett et al., 2008) but also involved in inflammation-associated cancer in the skin and colon (Langowski et al., 2006; Bollrath et al., 2009;…”
BackgroundLiang, S. C., Tan, X.-Y., Luxenberg, D. P., Karim, R., Dunussi-Joannopoulos, K., Collins, M., & Fouser, L. A. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20061308 · Cited by 2,330 · cited 8×
“It is now appreciated that a Type 17 cytokine expression signature is not restricted to Th-17 cells, and that cytokines such as IL-17 and IL-22 can be produced by unconventional T cell populations and more recently described RORtexpressing innate lymphoid populations (Pearson et al., 2012).”
BackgroundInfluentialCrypt stem cells as the cells-of-origin of intestinal cancer
Barker, N., Ridgway, R. A., van Es, J. H., van de Wetering, M., Begthel, H., van den Born, M., Danenberg, E., Clarke, A. R., Sansom, O. J., & Clevers, H. (2009) · Nature · doi:10.1038/nature07602 · Cited by 2,166 · cited 1×
“IL-22 may also promote cancer through direct effects on intestinal epithelial stem cells, previously shown to be key precursors for intestinal cancer (Barker et al., 2009).”
BackgroundGrivennikov, S., Karin, E., Terzic, J., Mucida, D., Yu, G.-Y., Vallabhapurapu, S., Scheller, J., Rose-John, S., Cheroutre, H., Eckmann, L., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.001 · Cited by 2,155 · cited 2×
“The role of Stat3 in colon cancer is well known but this has been attributed to activation by IL-6 and IL-11 (Ernst et al., 2008; Grivennikov et al., 2009).”
BackgroundFusobacterium nucleatum infection is prevalent in human colorectal carcinoma
Castellarin, M., Warren, R. L., Freeman, J. D., Dreolini, L., Krzywinski, M., Strauss, J., Barnes, R., Watson, P., Allen-Vercoe, E., Moore, R. A., et al. (2012) · Genome Research · doi:10.1101/gr.126516.111 · Cited by 2,043 · cited 1×
“Furthermore, certain species like the anaerobic Fusobacterium nucleatum were found to be associated with human CRC tissue (Castellarin et al., 2012; Kostic et al., 2012).”
BackgroundGenomic analysis identifies association of Fusobacterium with colorectal carcinoma
Kostic, A. D., Gevers, D., Pedamallu, C. S., Michaud, M., Duke, F., Earl, A. M., Ojesina, A. I., Jung, J., Bass, A. J., Tabernero, J., et al. (2012) · Genome Research · doi:10.1101/gr.126573.111 · Cited by 1,960 · cited 1×
“Furthermore, certain species like the anaerobic Fusobacterium nucleatum were found to be associated with human CRC tissue (Castellarin et al., 2012; Kostic et al., 2012).”
BackgroundInterleukin-22 mediates early host defense against attaching and effacing bacterial pathogens
Zheng, Y., Valdez, P. A., Danilenko, D. M., Hu, Y., Sa, S. M., Gong, Q., Abbas, A. R., Modrusan, Z., Ghilardi, N., de Sauvage, F. J., et al. (2008) · Nature Medicine · doi:10.1038/nm1720 · Cited by 1,921 · cited 8×
“IL-23 also drives colon cancer in an APC model, where it is induced in tumor-associated myeloid 928 Interleukin-22 in colon cancer | Kirchberger et al. (Reference numbers: 11/YH/0020 and 09/H0606/5) and informed written consent was given by all study patients.”
BackgroundInfluentialWu, S., Rhee, K.-J., Albesiano, E., Rabizadeh, S., Wu, X., Yen, H.-R., Huso, D. L., Brancati, F. L., Wick, E., McAllister, F., et al. (2009) · Nature Medicine · doi:10.1038/nm.2015 · Cited by 1,812 · cited 3×
“Th17 cell infiltration was also found in animal models of colon cancer, such as the ApcMin model driven by the enterotoxigenic bacterium Bacteroides fragilis, where blockade of IL-17 decreased tumor incidence (Wu et al., 2009).”
Background
Cited by
Items 301–400 of 529
IL-22 Negatively Regulates Helicobacter pylori-Induced CCL20 Expression in Gastric Epithelial Cells
Chen, J.-P., Wu, M., Kuo, S., & Liao, F. (2014) · PLoS ONE · doi:10.1371/journal.pone.0097350 · Cited by 26
“On the other hand, despite its protective role, IL-22 has also been reported to be associated with inflammatory diseases in skin [61,62] and colon [63].”
BackgroundFercher, C., Keshvari, S., McGuckin, M. A., & Barnard, R. T. (2017) · Experimental Biology and Medicine · doi:10.1177/1535370217748575 · Cited by 26
Peyer's patch innate lymphoid cells regulate commensal bacteria expansion
Hashiguchi, M., Kashiwakura, Y., Kojima, H., Kobayashi, A., Kanno, Y., & Kobata, T. (2015) · Immunology Letters · doi:10.1016/j.imlet.2015.03.002 · Cited by 25
Metabolic Regulation of Group 3 Innate Lymphoid Cells and Their Role in Inflammatory Bowel Disease
Song, D., Lai, L., & Ran, Z. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.580467 · Cited by 22
“Moreover, NKp46ILC3s drive the transition from colitis to CRC in Helicobacter hepaticus (Hh)+AOM mice and neutralization of IL-22 can ameliorate established colitis and reduce tumor burden (66).”
BackgroundYin, S., Yu, J., Hu, B., Lu, C., Liu, X., Gao, X., Li, W., Zhou, L., Wang, J., Wang, D., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02101 · Cited by 24
“Moreover, in Helicobacter hepaticus (Hh)-driven colitis, ILC3s accumulate in the inflamed colon and contribute to colitis through IL-23– driven IL-17 and IFN-γ production (15).”
IL-22-Expressing Murine Lymphocytes Display Plasticity and Pathogenicity in Reporter Mice
Shen, W., Hixon, J. A., McLean, M. H., Li, W., & Durum, S. K. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00662 · Cited by 27
“In contrast, roles of IL-22 in pathology of bowel (4, 5), liver (6), and skin (7) have also been reported.”
BackgroundCancer immune resistance: can theories converge?
Lu, R. O., Turan, T., Samayoa, J. A., & Marincola, F. M. (2017) · Emerging Topics in Life Sciences · doi:10.1042/etls20170060 · Cited by 22
ILC in chronic inflammation, cancer and targeting with biologicals
Pasquale, C. D., Campana, S., Bonaccorsi, I., Carrega, P., & Ferlazzo, G. (2021) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2021.100963 · Cited by 23
The role of ILC subsets in cancer
Bruchard, M., & Spits, H. (2022) · Seminars in Immunology · doi:10.1016/j.smim.2022.101654 · Cited by 25
Cytokine crowdsourcing: multicellular production of TH17-associated cytokines
Busman‐Sahay, K., Walrath, T., Huber, S., & O’Connor, W. (2014) · Journal of Leukocyte Biology · doi:10.1189/jlb.3ru0814-386r · Cited by 26
“[176] can drive this progression [177].”
Thomas, L. S., Targan, S. R., Tsuda, M., Yu, Q., Salumbides, B. C., Haritunians, T., Mengesha, E., McGovern, D. P. B., & Michelsen, K. S. (2016) · Journal of Leukocyte Biology · doi:10.1189/jlb.3a0316-129r · Cited by 21
Roles of cytotoxic and helper innate lymphoid cells in cancer
Guillerey, C. (2018) · Mammalian Genome · doi:10.1007/s00335-018-9781-4 · Cited by 22
Janus kinases in inflammatory bowel disease: Four kinases for multiple purposes
Galien, R. (2016) · Pharmacological Reports · doi:10.1016/j.pharep.2016.04.001 · Cited by 27
Wang, X., Undi, R. B., Ali, N., & Huycke, M. M. (2021) · Disease Models & Mechanisms · doi:10.1242/dmm.048793 · Cited by 22
Origins and evolution of innate lymphoid cells: Wardens of barrier immunity
Neill, D. R., & Flynn, R. (2018) · Parasite immunology (Print) · doi:10.1111/pim.12436 · Cited by 22
Neyazi, M., Bharadwaj, S. S., Bullers, S. J., Varényiová, Ž., Oxford IBD Cohort Study Investigators, Travis, S. P. L., Arancibia-Cárcamo, C. V., Powrie, F. M., & Geremia, A. (2021) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izab025 · Cited by 24
“11, 33 We confirmed that EpOCs respond to cytokine stimulation with STAT phosphorylation and gene induction.”
BackgroundHeterogeneity and diversity of group 3 innate lymphoid cells: new cells on the block
Satoh‐Takayama, N. (2015) · International Immunology · doi:10.1093/intimm/dxv054 · Cited by 22
The Role of Innate Immune Cells in Tumor Invasion and Metastasis
Huang, Y., Busuttil, R. A., & Boussioutas, A. (2021) · Cancers · doi:10.3390/cancers13235885 · Cited by 24
“Innate lymphoid cells pro-inflammation, immune regulation, pro- and anti-tumor local invasion, intravasation, extravasation, distant metastasis [139,145,149,152]”
BackgroundJeffery, R., Ilott, N. E., & Powrie, F. M. (2021) · Current Opinion in Microbiology · doi:10.1016/j.mib.2021.10.012 · Cited by 20
Lim, J. X., Lai, C., Mallett, G., McDonald, D., Hulme, G., Laba, S., Shapanis, A. G., Payne, M., Patterson, W., Alexander, M., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2216587120 · Cited by 19
“Similarly, IL-22-expressing ILC-3s have been implicated in protumor responses in bacteria-induced colon cancer (26, 27).”
Feedback mechanisms between M2 macrophages and Th17 cells in colorectal cancer patients
Mao, H., Pan, F., Guo, H., Bu, F., Xin, T., Chen, S., & Guo, Y. (2016) · Tumor Biology · doi:10.1007/s13277-016-5085-z · Cited by 20
“Uncontrolled IL-22 production increases the tumorigenic potential for colon cancer development in mouse models [14, 15].”
BackgroundInnate Lymphoid Cell Immunometabolism
O’Sullivan, T. E., & Sun, J. C.-Y. (2017) · Journal of Molecular Biology · doi:10.1016/j.jmb.2017.08.014 · Cited by 23
Innate Lymphoid Cells in Colorectal Cancers: A Double-Edged Sword
Huang, Q., Cao, W. H. J., Mielke, L. A., Seillet, C., Belz, G. T., & Jacquelot, N. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2019.03080 · Cited by 21
Unfolding innate mechanisms in the cancer microenvironment: The emerging role of the mesenchyme
Koliaraki, V., Henriques, A. R., Prados, A., & Kollias, G. A. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20190457 · Cited by 22
Intestinal tumor suppression in ApcMin/+ mice by prostaglandin D2 receptor PTGDR
Tippin, B. L., Kwong, A. M., Inadomi, M. J., Lee, O. J., Park, J. M., Materi, A. M., Buslon, V. S., Lin, A. M., Kudo, L. C., Karsten, S. L., et al. (2014) · Cancer Medicine · doi:10.1002/cam4.251 · Cited by 20
“In the intestinal mucosa, dendritic cells produce IL-23, to stimulate release of IL-22 by immune cells (innate lymphoid cells [40, 41], TH17 cells [42], and TH22 cells [43]).”
BackgroundEstablishment and function of tissue-resident innate lymphoid cells in the skin
Yang, J., Zhao, L., Xu, M., & Xiong, N. (2017) · Protein & Cell · doi:10.1007/s13238-017-0388-4 · Cited by 23
“IL-22 produced by ILC3s can contribute to development of colon cancer in a mouse model, consistent with the presence of IL-22-producing CD3 cells within human colorectal carcinoma tumors (Kirchberger et al., 2013).”
BackgroundInnate lymphoid cells involve in tumorigenesis
Tian, Z., van Velkinburgh, J. C., Wu, Y., & Ni, B. (2015) · International Journal of Cancer · doi:10.1002/ijc.29443 · Cited by 20
“controls) in the colonic lamina propria of mice with Helicobacter hepaticus -induced colitis.(12) Furthermore, in that study, the incidence rate of invasive adenocarcinoma was found to be substantially lower in the ILCs-depleted mice (9% vs.”
BackgroundInfluentialInnate lymphoid cells: A potential link between microbiota and immune responses against cancer
Panda, S. K., & Colonna, M. (2019) · Seminars in Immunology · doi:10.1016/j.smim.2019.03.003 · Cited by 23
IL-22 Confers EGFR-TKI Resistance in NSCLC via the AKT and ERK Signaling Pathways
Wang, X., Xu, J., Chen, J., Jin, S., Yao, J., Yu, T., Wang, W. T., & Guo, R. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01167 · Cited by 23
“IL-22 functions to regulate the inflammatory conditions of cancer (42), mediate cancer cell proliferation and migration, and modulate chemotherapeutic drug efficacy by altering the tumor microenvironment (30, 31).”
BackgroundIL-22 Gets to the Stem of Colorectal Cancer
Koltsova, E. K., & Grivennikov, S. I. (2014) · Immunity · doi:10.1016/j.immuni.2014.04.014 · Cited by 21
“IL-22 can be produced by innate lymphoid cells (ILC) in IBD and in CAC tumors of Rag2 / infected with H. hepaticus and injected with AOM (Kirchberger et al., 2013).”
BackgroundInfluentialEarly-Life Human Microbiota Associated With Childhood Allergy Promotes the T Helper 17 Axis in Mice
Petursdottír, D. H., Nordlander, S., Qazi, K. R., Carvalho‐Queiroz, C., Osman, O. A., Hell, É., Björkander, S., Haileselassie, Y., Navis, M., Kokkinou, E., et al. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01699 · Cited by 22
“Colonic lamina propria (cLP) leukocytes were isolated as previously described (17).”
MethodIdentification of a novel lymphoid population in the murine epidermis
Almeida, F. F., Tenno, M., Brzostek, J., Li, J. L. Y., Allies, G., Hoeffel, G., See, P., Ng, L. G., Fehling, H. J., Gascoigne, N. R. J., et al. (2015) · Scientific Reports · doi:10.1038/srep12554 · Cited by 21
Fung, K. Y., Nguyen, P. M., & Putoczki, T. L. (2017) · Molecular Immunology · doi:10.1016/j.molimm.2017.11.013 · Cited by 18
Lu, C., Klement, J. D., Smith, A. D., Yang, D., Waller, J. L., Browning, D. D., Munn, D. H., & Liu, K. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001365 · Cited by 22
Ling, L., Zhao, P., Yan, G., Chen, M., Zhang, T., Wang, L., & Jiang, Y. (2014) · Immunological Investigations · doi:10.3109/08820139.2014.936445 · Cited by 19
“Although IL-22CD3 T cells were detected in CRC tissues (Kirchberger et al., 2013), the status of Th22 responses during the development of CRC is not fully understood.”
BackgroundInnate Immunity in Helicobacter pylori Infection and Gastric Oncogenesis
Zhang, Y., Yan, Z., Jiao, Y., Feng, Y., Zhang, S., & Yang, A. (2025) · Helicobacter · doi:10.1111/hel.70015 · Cited by 25
Mechanistic studies of MALAT1 in respiratory diseases
Wu, W., Wang, S., Zhang, L., Mao, B., Wang, B., Wang, X., Zhao, D., Zhao, P., Mou, Y., & Yan, P. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.1031861 · Cited by 19
Gao, J., Cao, H., Zhang, Q., & Wang, B. (2020) · Sleep And Breathing · doi:10.1007/s11325-020-02204-z · Cited by 18
Innate lymphoid cells in colorectal cancer
Marchalot, A., & Mjösberg, J. (2022) · Scandinavian Journal of Immunology · doi:10.1111/sji.13156 · Cited by 18
Chen, Y., Newton, I. P., Vandereyken, M., Moraga, I., Näthke, I. S., & Swamy, M. (2019) · PLoS Biology · doi:10.1371/journal.pbio.3000540 · Cited by 18
“On the other hand, high levels of IL22 have been found in many CRC samples and are associated with CRC development [4,5,17].”
BackgroundInfluentialI don’t know about you, but I’m feeling IL-22
Dean, L. S., Threatt, A. N., Jones, K., Oyewole, E. O., Pauly, M., Wahl, M. J. L., Barahona, M., Reiter, R. W., & Nordgren, T. M. (2024) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2024.11.001 · Cited by 16
NK cell and ILC heterogeneity in colorectal cancer. New perspectives from high dimensional data
Pietropaolo, G., Scarno, G., Stabile, H., Grimaldi, A., Gismondi, A., Santoni, A., & Sciumè, G. (2021) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2021.100967 · Cited by 18
Roma, S., Carpen, L., Raveane, A., & Bertolini, F. (2021) · Cancers · doi:10.3390/cancers13205042 · Cited by 17
“However, an increased amount of intra-tumor levels of IL-22 has been found in CRC and this determines not only an upregulation of anti-apoptotic and pro-proliferating genes [135] but also the induction of abnormal epithelial cell proliferation, as observed in CRC mouse models [136].”
BackgroundInnate Immunity in Cancer Biology and Therapy
Zhang, Y., Xue, W., Xu, C., Nan, Y., Mei, S., Ju, D., Wang, S., & Zhang, X. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411233 · Cited by 21
“According to the type of tumor, ILC3s produce cytokines including IL-17 and IL-22 that promote or inhibit tumor development [77,78].”
BackgroundJanakiram, N. B., Mohammed, A., Bryant, T., Brewer, M. F., Biddick, L., Lightfoot, S. A., Lang, M. L., & Rao, C. V. (2014) · Molecular Carcinogenesis · doi:10.1002/mc.22168 · Cited by 16
Taming the Beast within: Regulation of Innate Lymphoid Cell Homeostasis and Function
Xu, W., & Santo, J. P. D. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1301759 · Cited by 19
Card9 as a critical regulator of tumor development
Zhong, X., Chen, B., Yang, L., & Yang, Z. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.03.001 · Cited by 17
RETRACTED: Living with Yourself: Innate Lymphoid Cell Immunometabolism
Rolot, M., & O’Sullivan, T. E. (2020) · Cells · doi:10.3390/cells9020334 · Cited by 16
RetractedMicroenvironmental modulation of the developing tumour: an immune‐stromal dialogue
Jones, J. O., Moody, W. M., & Shields, J. D. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12773 · Cited by 18
DEFB4A is a potential prognostic biomarker for colorectal cancer
Wu, Q., Wang, D., Zhang, Z., Wang, Y., Yu, W., Sun, K., Maimela, N. R., Sun, Z., Liu, J., Yuan, W., et al. (2020) · Oncology Letters · doi:10.3892/ol.2020.11975 · Cited by 20
Molecular pathways driving disease-specific alterations of intestinal epithelial cells
López-Posadas, R., Neurath, M. F., & Atreya, I. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2363-2 · Cited by 18
“Moreover, the STAT-3 triggering cytokine IL-22 could be identified as a potent inducer of IEC hyperproliferation and driver of colorectal cancer progression in a bacteria-induced model [270].”
BackgroundRationalizing heptadecaphobia: TH17 cells and associated cytokines in cancer and metastasis
Lücke, J., Shiri, A. M., Zhang, T., Kempski, J., Giannou, A. D., & Huber, S. (2021) · FEBS Journal · doi:10.1111/febs.15711 · Cited by 14
Effects of Immune Cells on Intestinal Stem Cells: Prospects for Therapeutic Targets
Ma, L., Yu, J., Zhang, H., Zhao, B. T., Zhang, J., Yang, D., Luo, F., Wang, B., Jin, B., & Liu, J. (2022) · Stem Cell Reviews and Reports · doi:10.1007/s12015-022-10347-7 · Cited by 16
Liu, F., Pan, X., Zhou, L., Zhou, J., Chen, B., Shi, J., Gao, W., & Lu, L. (2014) · DNA and Cell Biology · doi:10.1089/dna.2014.2432 · Cited by 15
“IL-22 sustains inflammation and cancer through its actions on epithelial cells, leading to a dysregulated inflammatory response and tissue repair, which promotes cancer (Kirchberger et al. , 2013).”
Innate Lymphoid Cells: Immunoregulatory Cells of Mucosal Inflammation
Kumar, V. (2014) · European Journal of Inflammation · doi:10.1177/1721727x1401200102 · Cited by 15
Marcucci, F., & Rumio, C. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03606-8 · Cited by 15
BTNL2 promotes colitis‐associated tumorigenesis in mice by regulating IL‐22 production
Peng, Q., Pan, T. S., He, R., Yi, M., Feng, L., Cui, Z., Gao, R., Wang, H., Feng, X., Li, H., et al. (2023) · EMBO Reports · doi:10.15252/embr.202256034 · Cited by 15
“…produced by ILC3s, CD4 + T cells, intestinal NKp46 + T cells, and cd T cells, while the regulation of IL-22 production in c tissue is still unclear (Satoh-Takayama et al , 2008; Broadhurst et al , 2010; Kirchberger et al , 2013; Mielke et al , 2013; Longman et al , 2014; Rankin et al , 2016).”
Fiordi, B., Salvestrini, V., Gugliotta, G., Castagnetti, F., Curti, A., Speiser, D. E., Marcenaro, E., Jandus, C., & Trabanelli, S. (2023) · Haematologica · doi:10.3324/haematol.2022.282140 · Cited by 20
Geng, Y., Liu, Z., Hu, R., Ma, W., Wu, X., Dong, H., Song, K., Xu, X., Huang, Y., Li, F., et al. (2023) · Journal of Ovarian Research · doi:10.1186/s13048-023-01236-9 · Cited by 16
“It can promote the psoriasis pathological progression, intestinal proliferation and even neoplasia [154, 155].”
BackgroundType 3 innate lymphoid cells are altered in colons of C57BL/6 mice with dioxin exposure
Li, Y., Xie, H. Q., Zhang, W., Wei, Y., Sha, R., Xu, S. L., Zhang, J., Jiang, Y., Guo, T. L., & Zhao, B. (2019) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2019.01.139 · Cited by 13
Wu, J., Lv, X., Zhu, S., Li, T., Cheng, H., & Chen, J. (2019) · Journal of Immunology Research · doi:10.1155/2019/1325181 · Cited by 17
Leite-Gomes, E., Dias, A. M., Azevedo, C. M., Santos‐Pereira, B., Magalhães, M., Garrido, M., Amorim, R., Lago, P. M., Marcos‐Pinto, R., & Pinho, S. S. (2021) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izab291 · Cited by 15
Wang, S., Wu, P., Chen, Y., & Chai, Y. (2020) · Oncology Letters · doi:10.3892/ol.2020.11736 · Cited by 15
Pires, S., Yang, W., Frigerio, S., Louis, C., Scott, C., Zhou, Y. L., Cardakli, E. D., Tran, N., Hassan‐Zahraee, M., Ye, Z., et al. (2026) · Immunity · doi:10.1016/j.immuni.2025.12.008 · Cited by 15
Oxidative Stress in the Tumor Immune Microenvironment: Mechanisms and Therapeutic Perspectives
Wang, Z., Li, B., Tang, P., Yan, F., Wang, S., Leng, G., Dawa, P., Chen, Y., Guo, Y., Yang, P., et al. (2026) · MedComm – Oncology · doi:10.1002/mog2.70068 · Cited by 18
Psoriasis-like skin disorder in transgenic mice expressing a RIG-I Singleton–Merten syndrome variant
Tayeh, A. A., Funabiki, M., Shimizu, S., Satoh, S., Lee, S., Iwakura, Y., Kato, H., & Fujita, T. (2020) · International Immunology · doi:10.1093/intimm/dxaa071 · Cited by 15
Group 3 innate lymphoid cells: A trained Gutkeeper
Serafini, N., & Santo, J. P. D. (2024) · Immunological Reviews · doi:10.1111/imr.13322 · Cited by 15
“149 Further investigation is required to understand the role of IL-22 and ILC3s in cancer, but the tissue environment likely regulates these responses.”
BackgroundInnate lymphoid cells and cancer at border surfaces with the environment
Mattiola, I., & Diefenbach, A. (2019) · Seminars in Immunology · doi:10.1016/j.smim.2019.06.001 · Cited by 13
Innate lymphoid cells in early tumor development
Warner, K., Ghaedi, M., Chung, D. C., Jacquelot, N., & Ohashi, P. S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.948358 · Cited by 14
“Dysregulated IL-23 mediated ILC3 activation and IL-17 and IL-22 production has been shown to promote gut inflammation and tumorigenesis (31, 32).”
BackgroundInnate lymphoid cells type 3 in cancer
Castillo‐González, R., Valle-Noguera, A., Gómez-Sánchez, M. J., Xia, P., & Cruz‐Adalia, A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1033252 · Cited by 13
“Analyses of the underlying mechanisms revealed that signal transducer and activator of transcription 3 (STAT3) phosphorylation and proliferation of epithelial cells was specifically induced by ILC3s-derived IL-22, promoting the initiation, growth and maintenance of tumors (17).”
BackgroundIL-22BP production is heterogeneously distributed in Crohn’s disease
Fantou, A., Lagrue, E., Laurent, T., Bouchet‐Delbos, L., Blandin, S., Jarry, A., Bériou, G., Braudeau, C., Salabert, N., Marín, E., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1034570 · Cited by 15
“When 64 dysregulated, however, IL-22 actions on IEC can promote tumor cell proliferation (9,10).”
BackgroundIL-22: linking inflammation and cancer
Harrison, C. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4065 · Cited by 13
Role of type 2 innate lymphoid cell and its related cytokines in tumor immunity
Wan, J., Cai, W., Wang, H., Cheng, J., Su, Z., Wang, S., & Xu, H. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.29287 · Cited by 11
Innate Lymphoid Cells and Inflammatory Bowel Disease
Peng, V., Jaeger, N., & Colonna, M. (2022) · Advances in experimental medicine and biology · doi:10.1007/978-981-16-8387-9_7 · Cited by 13
A Critical Role of the IL-22–IL-22 Binding Protein Axis in Hepatocellular Carcinoma
Giannou, A. D., Lücke, J., Kleinschmidt, D., Shiri, A. M., Steglich, B., Nawrocki, M., Zhang, T., Zazara, D. E., Kempski, J., Zhao, L., et al. (2022) · Cancers · doi:10.3390/cancers14246019 · Cited by 12
Drommi, F., Calabrò, A., Vento, G., Pezzino, G., Cavaliere, R., Omero, F., Muscolino, P., Granata, B., D’Anna, F., Silvestris, N., et al. (2023) · Cancers · doi:10.3390/cancers15112893 · Cited by 14
“Indeed, during Hhep-driven cancers, ILC3s have also been suggested to play a pro-tumorigenic function since pathogenic double-negative Nkp46− CD4− ILC3s increase and their IL-22 production can promote tumorigenesis by supporting epithelial cell proliferation through Stat3 phosphorylation [56].”
BackgroundPanagi, M., Georgila, K., Eliopoulos, A. G., & Apidianakis, Y. (2015) · Oncotarget · doi:10.18632/oncotarget.6463 · Cited by 14
“Polymorphisms within the pro-inflammatory cytokines IL-1, IL-6 and IL-22 and STAT3 pathway activation may boost mucosal cytokine expression and enterocyte regeneration, thereby facilitating gastrointestinal cancer [29-31].”
BackgroundPorter, R. J., Andrews, C., Brice, D., Durum, S. K., & McLean, M. H. (2018) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izy230 · Cited by 15
Effective Barriers: The Role of NKT Cells and Innate Lymphoid Cells in the Gut
Cairo, C., & Webb, T. J. (2022) · The Journal of Immunology · doi:10.4049/jimmunol.2100799 · Cited by 11
Bertin, L., Barberio, B., Gubbiotti, A., Bertani, L., Costa, F., Ceccarelli, L., Visaggi, P., Bodini, G., Pasta, A., Sablich, R., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13061539 · Cited by 12
Zhang, J., Yu, M., Zhang, T., Song, X., Ying, S., Shen, Z., & Yu, C. (2024) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjae134 · Cited by 17
Bladder tumor ILC1s undergo Th17‐like differentiation in human bladder cancer
Mukherjee, N. Z., Ji, N., Tan, X., Lin, C., Rios, E. M., Chen, C., Huang, T. H. ‐., & Svatek, R. S. (2021) · Cancer Medicine · doi:10.1002/cam4.4243 · Cited by 10
Jothimani, G., Ganesan, H., Pathak, S., & Banerjee, A. (2022) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026622666220401161511 · Cited by 11
Jiao, Y., Yan, Z., & Yang, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076652 · Cited by 13
Hunzeker, Z. E., Zhao, L., Kim, A. M., Parker, J. M., Zhu, Z., Xiao, H., Bai, Q., Wakefield, M. R., & Fang, Y. (2024) · Medical Oncology · doi:10.1007/s12032-024-02481-8 · Cited by 14
Gut bacteria affect the tumoral immune milieu: distorting the efficacy of immunotherapy or not?
Pu, X., Chao, G., Dong, L., & Chang, P. (2020) · Gut Microbes · doi:10.1080/19490976.2020.1739794 · Cited by 11
“However, in colorectal cancer, IL-22 is able to promote tumor progression.(78) In the latter situation, administration of the L.”
BackgroundCytokines and Regulating Epithelial Cell Division
Marzoog, B. A. (2024) · Current Drug Targets · doi:10.2174/0113894501279979240101051345 · Cited by 12
Ambiguous roles of innate lymphoid cells in chronic development of liver diseases
Shen, Y. L., Li, J., Wang, S., & Jiang, W. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i18.1962 · Cited by 12
Immune Cells in Hyperprogressive Disease under Immune Checkpoint-Based Immunotherapy
Wei, Z., & Zhang, Y. (2022) · Cells · doi:10.3390/cells11111758 · Cited by 10
“[140] reported that IL-22 produced by ILC3s reduced gastrointestinal cancer growth in colon cancer-model mice.”
BackgroundFriends close, enemies closer: the complex role of the microbiome in antitumor immunity
Patra, D., Dev, G., Hand, T. W., & Overacre-Delgoffe, A. E. (2025) · Current Opinion in Immunology · doi:10.1016/j.coi.2025.102537 · Cited by 11
Innate lymphoid cells: potential targets for cancer therapeutics
Ng, C. K., & Belz, G. T. (2022) · Trends in cancer · doi:10.1016/j.trecan.2022.10.007 · Cited by 9
RORγT agonists as immune modulators in anticancer therapy.
Pastwińska, J., Karwaciak, I., Karaś, K., Bachorz, R. A., & Ratajewski, M. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.189021 · Cited by 16
Molecular signature of interleukin-22 in colon carcinoma cells and organoid models
Rudloff, I., Jardé, T., Bachmann, M., Elgass, K., Kerr, G., Engel, R. M., Richards, E. A., Oliva, K., Wilkins, S., McMurrick, P. J., et al. (2019) · Translational research · doi:10.1016/j.trsl.2019.10.004 · Cited by 11
Helper Innate Lymphoid Cells in Human Tumors: A Double-Edged Sword?
Tumino, N., Vacca, P., Quatrini, L., Munari, E., Moretta, F., Pelosi, A., Mariotti, F. R., & Moretta, L. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2019.03140 · Cited by 10
“In addition, the production of IL-22 by NKp46ILC3 was shown to play a role in tumor maintenance in a bacteria-induced colon cancer model (38).”
BackgroundInnate Lymphoid Cells: Emerging Players in Pancreatic Disease
Shi, S., Ye, L., Jin, K., Xiao, Z., Yu, X., & Wu, W. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073748 · Cited by 11
The soldiers needed to be awakened: Tumor-infiltrating immune cells
Yaping, W., Wang, Z., Zhuling, C., Li, R., Pengyu, F., Lili, G., Cheng, J., Bo, Z., Liu, L., Guangdong, H., et al. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.988703 · Cited by 12
“In CRC, ILC3s produced IL22 which activated STAT3 phosphorylation signaling to promote the development and invasion of tumor (Kirchberger et al., 2013).”
BackgroundIL-22 promotes the proliferation of cancer cells in smoking colorectal cancer patients
Song, B., Ma, Y., Liu, X., Li, W., Zhang, J., Liu, J., & Han, J. (2015) · Tumor Biology · doi:10.1007/s13277-015-3916-y · Cited by 11
Innate lymphoid cells in antitumor immunity
Salomé, B., & Jandus, C. (2017) · Journal of Leukocyte Biology · doi:10.1189/jlb.5mr0617-266r · Cited by 9
Poniewierska-Baran, A., Tokarz–Deptuła, B., & Deptuła, W. (2021) · Archives of Medical Science · doi:10.5114/aoms.2019.89835 · Cited by 10
“IL-22 produced by ILC-3 cells may be responsible for promoting colorectal cancer [11, 12].”
BackgroundColorectal Liver Metastasis: Can Cytokines Make the Difference?
Ballarò, C., Quaranta, V., & Giannelli, G. (2023) · Cancers · doi:10.3390/cancers15225359 · Cited by 10
“Indeed, although inhibiting IL-17 reduces intestinal inflammation, only IL-22 neutralization has been shown to significantly reduce the dysplasia and tumor burden in a mouse model of CRC [125].”
Background
Metadata
- Authors
- Kirchberger, S., Royston, D. J., Boulard, O., Thornton, E., Franchini, F., Szabady, R. L., Harrison, O., & Powrie, F.
- Affiliations
- John Radcliffe Hospital (GB)
- University of Oxford (GB)
- Corresponding author
- Powrie, Fiona
- ORCID
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2013-04-15
- Volume
- 210
- Issue
- 5
- Pages
- 917-931
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC3646494
- OpenAlex
- W2124499950
- Cited by
- 529
- References
- 52
- Citations by year
- 2026: 18 · 2025: 12 · 2024: 24 · 2023: 33 · 2022: 39 · 2021: 34 · 2020: 54 · 2019: 51 · 2018: 42 · 2017: 55 · 2016: 48 · 2015: 54 · 2014: 50 · 2013: 12
- FWCI
- 30.21
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Experimental Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by-nc-sa)
- Funders
- Royal College of Pathologists of Australasia
- Wellcome Trust (095688/Z/11/Z, 095688)
- Cancer Research UK (A7297, A11663)
- National Institute for Health and Care Research
- European Commission (223151)
- Jean Shanks Foundation
- Austrian Science Fund
- Genentech
- Biotechnology and Biological Sciences Research Council (BB/I005609/1)
- NIHR Oxford Biomedical Research Centre
- UCB Celltech
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › IL-33, ST2, and ILC Pathways
- Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Keywords
- colon cancer, IL-22, IL-17, innate lymphoid cells, inflammatory bowel disease, STAT3 phosphorylation, epithelial cell proliferation, therapeutic target
- MeSH terms
- Interleukin-22, Animals, Antigens, Ly, Cell Transformation, Neoplastic, Colitis, Colon, Colonic Neoplasms, Disease Models, Animal, Epithelial Cells, Humans, Interleukins, Lymphocytes, Phosphorylation, CD4 Antigens, Gene Expression Regulation, Neoplastic, Helicobacter, Disease Progression, Cell Lineage, STAT3 Transcription Factor, Mice, Natural Cytotoxicity Triggering Receptor 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.